Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed. Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective

Read more